Multiple Myeloma Clinical Trial
Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)
Summary
Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood cells). Most trial participants with MM relapse (cancer has come back) or become non- responsive to treatment and remission gets shorter after each line of treatment. This is a study to assess t(11;14) and BCL2 expression in adult participants with newly diagnosed and relapsed/refractory (R/R) MM.
Approximately 500 adult participants with newly confirmed or relapsed/refractory (R/R) multiple myeloma (MM) will be enrolled in around 15-20 countries.
Participants will receive standard of care while participating in this study. No drug will be administered as a part of this study.
Participants will attend regular visits during the course of the study at a hospital or clinic and will be asked to provide bone marrow and blood samples.
Eligibility Criteria
Inclusion Criteria:
- Confirmed newly diagnosed or relapsed/refractory (R/R) Multiple myeloma (MM) who have signed informed consent for the use of their biological material for research purposes.
Exclusion Criteria:
- Participants who do not have Bone Marrow (BM) and blood sample at time of diagnosis or at confirmation of relapse.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 40 Locations for this study
New Orleans Louisiana, 70112, United States
Dallas Texas, 75390, United States
Ciudad Autonoma Buenos Aires Ciuadad Autonoma De Buenos Aires, 1199, Argentina
Melbourne Victoria, 3004, Australia
Salvador Bahia, 41253, Brazil
Porto Alegre Rio Grande Do Sul, 90035, Brazil
São Paulo Sao Paulo, 04537, Brazil
São Paulo Sao Paulo, 05652, Brazil
Rio de Janeiro , 22793, Brazil
Sao Paulo , 01323, Brazil
Sao Paulo , 05403, Brazil
Edmonton Alberta, T6G 1, Canada
Zagreb Grad Zagreb, 10000, Croatia
Hradec Kralove , 500 0, Czechia
Ostrava , 708 5, Czechia
Lille Hauts-de-France, 59037, France
Nantes Pays-de-la-Loire, 44000, France
Paris , 75015, France
Berlin , 10715, Germany
Hamburg , 22763, Germany
Athens Attiki, 11528, Greece
Beaumont Dublin, D09 X, Ireland
Jerusalem Yerushalayim, 91120, Israel
Ancona , 60126, Italy
Milano , 20162, Italy
Maastricht , 6229 , Netherlands
Oslo , 0450, Norway
Warszawa Mazowieckie, 02-77, Poland
Poznan Wielkopolskie, 60-56, Poland
Sector 2 Bucuresti, 02232, Romania
Jeddah , 22384, Saudi Arabia
Ljubljana , 1000, Slovenia
Badalona Barcelona, 08916, Spain
Barcelona , 08036, Spain
Leon , 24071, Spain
Madrid , 28040, Spain
Madrid , 28041, Spain
Salamanca , 37711, Spain
Taichung , 40705, Taiwan
Istanbul , 34214, Turkey
How clear is this clinincal trial information?